The effect of preservative free tafluprost on intraocular pressure in patients with ocular hypertension or primary open angle glaucoma

Purpose Since increased intraocular pressure (IOP) is the most important modifiable risk factor for the development and progression of glaucoma, potent and save IOP lowering therapy is of special importance. Preservative free prostaglandins offer a new treatment option using a potent topical drug wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta ophthalmologica (Oxford, England) England), 2014-09, Vol.92 (s253), p.0-0
Hauptverfasser: HOMMER, A, KROMUS, M, SCHMIDL, D, GARHOFER, G, SCHMETTERER, L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 0
container_issue s253
container_start_page 0
container_title Acta ophthalmologica (Oxford, England)
container_volume 92
creator HOMMER, A
KROMUS, M
SCHMIDL, D
GARHOFER, G
SCHMETTERER, L
description Purpose Since increased intraocular pressure (IOP) is the most important modifiable risk factor for the development and progression of glaucoma, potent and save IOP lowering therapy is of special importance. Preservative free prostaglandins offer a new treatment option using a potent topical drug without the disadvantages of a co‐administered preservatives. The aim of the present study was to investigate the effect of 8 weeks treatment with preservative free tafluprost on IOP in patients with glaucoma or ocular hypertension. Methods 16 patients with either primary open angle glaucoma with an uncontrolled intraocular pressure ≥ 30mmHg or patients with ocular hypertension with an IOP ≥ 30mmHg were included in the present open pilot study. For patients who were already on antiglaucoma therapy, a washout period with a duration of 4 weeks was scheduled. IOP was measured at 8am and 6pm after the washout period as well as 4 and 8 weeks of after start of topical drug treatment. Results A total of 16 patients (age range 31‐76 years) were included in the study. After the 4 week washout period, mean IOP was 35.6±4.5mmHg at the morning and 32.9±5.4mmHg at the evening measurement. 4 weeks after treatment start, a decrease in IOP by ‐31%±12% to 24.4±4.6mmHg (p
doi_str_mv 10.1111/j.1755-3768.2014.T023.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1554643109</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3408330201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1783-446935bf9686fa81c9463c6814aafdc089a1fdee2d29c3badef1a7a6cea8a4433</originalsourceid><addsrcrecordid>eNqNkF1LwzAUhosoOKe_wYDXrU2Tpi14M4ZfMNiFE7wLZ-nJ1tK1NWn38Qf83aZu7Nrc5HDyPknO43n3NAyoW49lQJM49lki0iAKKQ8WYcSC_YU3Ovcvz3X8de3dWFuGoaBC8JH3s1gjQa1RdaTRpDVo0WyhK7ZItEEkHeiqb01j3XlNiroz0Ki-AvOXtb1B1yStI7DuLNkV3ZqcAutDi6bD2haObAag2IA5kKbFmkC9qpCsKuhVs4Fb70pDZfHutI-9z5fnxfTNn81f36eTma9okjKfc5GxeKkzkQoNKVUZF0yJlHIAnaswzYDqHDHKo0yxJeSoKSQgFEIKnDM29h6O97qJvnu0nSyb3tTuSUnjmAvOaJi5VHJMKTe3Najl6euShnKQLks5CJWDXDlIl4N0uXfk05HcFRUe_ovJyfxjqNgvFF2Mrg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1554643109</pqid></control><display><type>article</type><title>The effect of preservative free tafluprost on intraocular pressure in patients with ocular hypertension or primary open angle glaucoma</title><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Free Content</source><creator>HOMMER, A ; KROMUS, M ; SCHMIDL, D ; GARHOFER, G ; SCHMETTERER, L</creator><creatorcontrib>HOMMER, A ; KROMUS, M ; SCHMIDL, D ; GARHOFER, G ; SCHMETTERER, L</creatorcontrib><description>Purpose Since increased intraocular pressure (IOP) is the most important modifiable risk factor for the development and progression of glaucoma, potent and save IOP lowering therapy is of special importance. Preservative free prostaglandins offer a new treatment option using a potent topical drug without the disadvantages of a co‐administered preservatives. The aim of the present study was to investigate the effect of 8 weeks treatment with preservative free tafluprost on IOP in patients with glaucoma or ocular hypertension. Methods 16 patients with either primary open angle glaucoma with an uncontrolled intraocular pressure ≥ 30mmHg or patients with ocular hypertension with an IOP ≥ 30mmHg were included in the present open pilot study. For patients who were already on antiglaucoma therapy, a washout period with a duration of 4 weeks was scheduled. IOP was measured at 8am and 6pm after the washout period as well as 4 and 8 weeks of after start of topical drug treatment. Results A total of 16 patients (age range 31‐76 years) were included in the study. After the 4 week washout period, mean IOP was 35.6±4.5mmHg at the morning and 32.9±5.4mmHg at the evening measurement. 4 weeks after treatment start, a decrease in IOP by ‐31%±12% to 24.4±4.6mmHg (p&lt;0.01) was observed at the morning measurement and by ‐34%±14% to 21.6±4.6mmHg (p&lt;0.01) at the evening measurement. 8 weeks after treatment start IOP remained low, on average 24.4±4.6mmHg (‐31%±13% compared to baseline, p&lt;0.01) in the morning and 21.9±3.9mmHg (‐32%±16% compared to baseline, p&lt;0.01) in the evening. Conclusion The present data indicate that treatment with preservative free saflutan is safe and has the capacity to significantly decrease IOP in patients with primary open angle glaucoma and ocular hypertension. Further studies are needed to investigate the effect of preservative free formulations for long term treatment.</description><identifier>ISSN: 1755-375X</identifier><identifier>EISSN: 1755-3768</identifier><identifier>DOI: 10.1111/j.1755-3768.2014.T023.x</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Drug therapy ; Glaucoma ; Hypertension ; Ophthalmology</subject><ispartof>Acta ophthalmologica (Oxford, England), 2014-09, Vol.92 (s253), p.0-0</ispartof><rights>2014 Acta Ophthalmologica</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1755-3768.2014.T023.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27903,27904,45554,46812</link.rule.ids></links><search><creatorcontrib>HOMMER, A</creatorcontrib><creatorcontrib>KROMUS, M</creatorcontrib><creatorcontrib>SCHMIDL, D</creatorcontrib><creatorcontrib>GARHOFER, G</creatorcontrib><creatorcontrib>SCHMETTERER, L</creatorcontrib><title>The effect of preservative free tafluprost on intraocular pressure in patients with ocular hypertension or primary open angle glaucoma</title><title>Acta ophthalmologica (Oxford, England)</title><description>Purpose Since increased intraocular pressure (IOP) is the most important modifiable risk factor for the development and progression of glaucoma, potent and save IOP lowering therapy is of special importance. Preservative free prostaglandins offer a new treatment option using a potent topical drug without the disadvantages of a co‐administered preservatives. The aim of the present study was to investigate the effect of 8 weeks treatment with preservative free tafluprost on IOP in patients with glaucoma or ocular hypertension. Methods 16 patients with either primary open angle glaucoma with an uncontrolled intraocular pressure ≥ 30mmHg or patients with ocular hypertension with an IOP ≥ 30mmHg were included in the present open pilot study. For patients who were already on antiglaucoma therapy, a washout period with a duration of 4 weeks was scheduled. IOP was measured at 8am and 6pm after the washout period as well as 4 and 8 weeks of after start of topical drug treatment. Results A total of 16 patients (age range 31‐76 years) were included in the study. After the 4 week washout period, mean IOP was 35.6±4.5mmHg at the morning and 32.9±5.4mmHg at the evening measurement. 4 weeks after treatment start, a decrease in IOP by ‐31%±12% to 24.4±4.6mmHg (p&lt;0.01) was observed at the morning measurement and by ‐34%±14% to 21.6±4.6mmHg (p&lt;0.01) at the evening measurement. 8 weeks after treatment start IOP remained low, on average 24.4±4.6mmHg (‐31%±13% compared to baseline, p&lt;0.01) in the morning and 21.9±3.9mmHg (‐32%±16% compared to baseline, p&lt;0.01) in the evening. Conclusion The present data indicate that treatment with preservative free saflutan is safe and has the capacity to significantly decrease IOP in patients with primary open angle glaucoma and ocular hypertension. Further studies are needed to investigate the effect of preservative free formulations for long term treatment.</description><subject>Drug therapy</subject><subject>Glaucoma</subject><subject>Hypertension</subject><subject>Ophthalmology</subject><issn>1755-375X</issn><issn>1755-3768</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqNkF1LwzAUhosoOKe_wYDXrU2Tpi14M4ZfMNiFE7wLZ-nJ1tK1NWn38Qf83aZu7Nrc5HDyPknO43n3NAyoW49lQJM49lki0iAKKQ8WYcSC_YU3Ovcvz3X8de3dWFuGoaBC8JH3s1gjQa1RdaTRpDVo0WyhK7ZItEEkHeiqb01j3XlNiroz0Ki-AvOXtb1B1yStI7DuLNkV3ZqcAutDi6bD2haObAag2IA5kKbFmkC9qpCsKuhVs4Fb70pDZfHutI-9z5fnxfTNn81f36eTma9okjKfc5GxeKkzkQoNKVUZF0yJlHIAnaswzYDqHDHKo0yxJeSoKSQgFEIKnDM29h6O97qJvnu0nSyb3tTuSUnjmAvOaJi5VHJMKTe3Najl6euShnKQLks5CJWDXDlIl4N0uXfk05HcFRUe_ovJyfxjqNgvFF2Mrg</recordid><startdate>201409</startdate><enddate>201409</enddate><creator>HOMMER, A</creator><creator>KROMUS, M</creator><creator>SCHMIDL, D</creator><creator>GARHOFER, G</creator><creator>SCHMETTERER, L</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>201409</creationdate><title>The effect of preservative free tafluprost on intraocular pressure in patients with ocular hypertension or primary open angle glaucoma</title><author>HOMMER, A ; KROMUS, M ; SCHMIDL, D ; GARHOFER, G ; SCHMETTERER, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1783-446935bf9686fa81c9463c6814aafdc089a1fdee2d29c3badef1a7a6cea8a4433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Drug therapy</topic><topic>Glaucoma</topic><topic>Hypertension</topic><topic>Ophthalmology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HOMMER, A</creatorcontrib><creatorcontrib>KROMUS, M</creatorcontrib><creatorcontrib>SCHMIDL, D</creatorcontrib><creatorcontrib>GARHOFER, G</creatorcontrib><creatorcontrib>SCHMETTERER, L</creatorcontrib><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Acta ophthalmologica (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HOMMER, A</au><au>KROMUS, M</au><au>SCHMIDL, D</au><au>GARHOFER, G</au><au>SCHMETTERER, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of preservative free tafluprost on intraocular pressure in patients with ocular hypertension or primary open angle glaucoma</atitle><jtitle>Acta ophthalmologica (Oxford, England)</jtitle><date>2014-09</date><risdate>2014</risdate><volume>92</volume><issue>s253</issue><spage>0</spage><epage>0</epage><pages>0-0</pages><issn>1755-375X</issn><eissn>1755-3768</eissn><abstract>Purpose Since increased intraocular pressure (IOP) is the most important modifiable risk factor for the development and progression of glaucoma, potent and save IOP lowering therapy is of special importance. Preservative free prostaglandins offer a new treatment option using a potent topical drug without the disadvantages of a co‐administered preservatives. The aim of the present study was to investigate the effect of 8 weeks treatment with preservative free tafluprost on IOP in patients with glaucoma or ocular hypertension. Methods 16 patients with either primary open angle glaucoma with an uncontrolled intraocular pressure ≥ 30mmHg or patients with ocular hypertension with an IOP ≥ 30mmHg were included in the present open pilot study. For patients who were already on antiglaucoma therapy, a washout period with a duration of 4 weeks was scheduled. IOP was measured at 8am and 6pm after the washout period as well as 4 and 8 weeks of after start of topical drug treatment. Results A total of 16 patients (age range 31‐76 years) were included in the study. After the 4 week washout period, mean IOP was 35.6±4.5mmHg at the morning and 32.9±5.4mmHg at the evening measurement. 4 weeks after treatment start, a decrease in IOP by ‐31%±12% to 24.4±4.6mmHg (p&lt;0.01) was observed at the morning measurement and by ‐34%±14% to 21.6±4.6mmHg (p&lt;0.01) at the evening measurement. 8 weeks after treatment start IOP remained low, on average 24.4±4.6mmHg (‐31%±13% compared to baseline, p&lt;0.01) in the morning and 21.9±3.9mmHg (‐32%±16% compared to baseline, p&lt;0.01) in the evening. Conclusion The present data indicate that treatment with preservative free saflutan is safe and has the capacity to significantly decrease IOP in patients with primary open angle glaucoma and ocular hypertension. Further studies are needed to investigate the effect of preservative free formulations for long term treatment.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><doi>10.1111/j.1755-3768.2014.T023.x</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1755-375X
ispartof Acta ophthalmologica (Oxford, England), 2014-09, Vol.92 (s253), p.0-0
issn 1755-375X
1755-3768
language eng
recordid cdi_proquest_journals_1554643109
source Wiley Online Library Journals Frontfile Complete; Wiley Free Content
subjects Drug therapy
Glaucoma
Hypertension
Ophthalmology
title The effect of preservative free tafluprost on intraocular pressure in patients with ocular hypertension or primary open angle glaucoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T12%3A51%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20preservative%20free%20tafluprost%20on%20intraocular%20pressure%20in%20patients%20with%20ocular%20hypertension%20or%20primary%20open%20angle%20glaucoma&rft.jtitle=Acta%20ophthalmologica%20(Oxford,%20England)&rft.au=HOMMER,%20A&rft.date=2014-09&rft.volume=92&rft.issue=s253&rft.spage=0&rft.epage=0&rft.pages=0-0&rft.issn=1755-375X&rft.eissn=1755-3768&rft_id=info:doi/10.1111/j.1755-3768.2014.T023.x&rft_dat=%3Cproquest_cross%3E3408330201%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1554643109&rft_id=info:pmid/&rfr_iscdi=true